A caucasian male in his fifth decade of life, non-smoker, presented with ALK-positive non-small cell lung cancer (NSCLC). The case highlights the complex journey of ALK-positive patients and demonstrates the efficacy and tolerability of new ALK target therapies, allowing patients to maintain their routines without compromising the effectiveness of the therapy. The case report aims to outline the enhancement of both overall survival (OS) and quality of life (QoL) granted by ALK-targeted therapy within the rapidly evolving treatment landscape of NSCLC.
